Nuevolution Appoints Henrik Simonsen
News Sep 17, 2015
Nuevolution A/S has announced that Henrik Simonsen has joined the company in the position as Chief Financial Officer. In his role, Mr. Simonsen will lead Nuevolution’s financial strategy including corporate finance and investor relations.
As member of Nuevolution’s Executive Management, he will play a key part in the strategy planning going forward. His most recent position was at SEB, where he was Sector Responsible for the Life Science arm of the Corporate Finance practice.
With Henrik Simonsen, Nuevolution appoints a seasoned professional, who has over 20 years of experience as an equity analysts covering Nordic, European and US life science companies as well as a number of years of corporate finance experience including several biotech IPO’s in Scandinavia.
“The appointment of Henrik Simonsen, to take charge of Nuevolution’s financial strategy and investor relations, represents an important step for Nuevolution in realization of our ambitious strategy of establishing a broad portfolio of clinical and pre-clinical programs within oncology, immunology and immuno-oncology.” said Alex Gouliaev, CEO of Nuevolution A/S and continued “Our programs addresses diseases with significant unmet need, and should therefore be developed as rapidly as possible. With Henrik’s strong corporate finance experience and investor network, we are confident that he will play a key role in helping secure future financing needed in realization of these important goals.”
“I am thrilled to be joining Nuevolution, which has developed the state-of-the art drug discovery platform, Chemetics, collaborates with leading drug companies and is building a promising pipeline in oncology, immuno-oncology and inflammation”, says Henrik Simonsen.
Most recently, Henrik served as Director and Sector Responsible for Life Science within Corporate Finance at SEB, where he was leading a number of Initial Public Offerings, venture capital raising initiatives as well as acting as an advisor to the executive management of several pharmaceutical and biotech companies.
Prior to SEB Corporate Finance, Henrik was Senior Equity Analyst at SEB and at Nordea Securities. Henrik obtained his Master of Science in Economics degree from the University of Copenhagen.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019